Linezolid manifests a rapid and dramatic therapeutic effect for patients with life-threatening tuberculous meningitis

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 10, 2014, Pages 6297-6301

  Sun, Feng ^a   Ruan, Qiaoling ^a   Wang, Jiali ^a   Chen, Shu ^a   Jin, Jialin ^a   Shao, Lingyun ^a   Zhang, Ying ^a,b   Zhang, Wenhong ^a  

^a FUDAN UNIVERSITY   (China)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; LINEZOLID; ACETAMIDE DERIVATIVE; OXAZOLIDINONE DERIVATIVE; TUBERCULOSTATIC AGENT;

ADULT; APPARENT LIFE THREATENING EVENT; ARTICLE; BONE MARROW SUPPRESSION; BRAIN SCINTISCANNING; CEREBROSPINAL FLUID CULTURE; CLINICAL ARTICLE; COHORT ANALYSIS; CONSCIOUSNESS; CONSCIOUSNESS DISORDER; CONVALESCENCE; DRUG WITHDRAWAL; FEMALE; GLUCOSE BRAIN LEVEL; HEADACHE; HUMAN; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; MOUTH TEMPERATURE; MUSCLE RIGIDITY; MYCOBACTERIUM TUBERCULOSIS; NECK PAIN; NEUROIMAGING; NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE DISEASE; PROTEIN CEREBROSPINAL FLUID LEVEL; RETROSPECTIVE STUDY; SURVIVAL RATE; THERAPY EFFECT; TREATMENT WITHDRAWAL; TUBERCULOUS MENINGITIS; VISUAL DISORDER; MIDDLE AGED; TREATMENT OUTCOME; TUBERCULOSIS, MENINGEAL;

ACETAMIDES; ADULT; ANTITUBERCULAR AGENTS; FEMALE; HUMANS; LINEZOLID; MALE; MIDDLE AGED; OXAZOLIDINONES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUBERCULOSIS, MENINGEAL;

EID: 84907267799     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02784-14     Document Type: Article

References (30)

1. Galimi R. 2011. Extrapulmonary tuberculosis: tuberculous meningitis new developments. Eur. Rev. Med. Pharmacol. Sci. 15:365-386.
2. Chatterjee S. 2011. Brain tuberculomas, tubercular meningitis, and posttubercular hydrocephalus in children. J. Pediatr. Neurosci. 6:S96-S100. http://dx.doi.org/10.4103/1817-1745.85725.
3. Lu CH, Chang WN, Chang HW. 2001. The prognostic factors of adult tuberculous meningitis. Infection 29:299-304. http://dx.doi.org/10.1007/s15010-001-1100-3.
4. Girgis NI, Sultan Y, Farid Z, Mansour MM, Erian MW, Hanna LS, Mateczun AJ. 1998. Tuberculosis meningitis, Abbassia Fever Hospital-Naval Medical Research Unit No. 3-Cairo, Egypt, from 1976 to 1996. Am. J. Trop. Med. Hyg. 58:28-34.
5. Duo L, Ying B, Song X, Lu X, Ye Y, Fan H, Xin J, Wang L. 2011. Molecular profile of drug resistance in tuberculous meningitis from southwest China. Clin. Infect. Dis. 53:1067-1073. http://dx.doi.org/10.1093/cid/cir663.
6. Leach KL, Brickner SJ, Noe MC, Miller PE. 2011. Linezolid, the first oxazolidinone antibacterial agent. Ann. N. Y. Acad. Sci. 1222:49-54. http: //dx.doi.org/10.1111/j.1749-6632.2011.05962.x.
7. Anger HA, Dworkin F, Sharma S, Munsiff SS, Nilsen DM, Ahuja SD. 2010. Linezolid use for treatment of multidrug-resistant and extensively drug-resistant tuberculosis, New York City, 2000-06. J. Antimicrob. Chemother. 65:775-783. http://dx.doi.org/10.1093/jac/dkq017.
8. Condos R, Hadgiangelis N, Leibert E, Jacquette G, Harkin T, Rom WN. 2008. Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis. Chest 134:187-192. http://dx.doi.org/10.1378/chest.07-1988.
9. Fortún J, Martin-Davila P, Navas E, Perez-Elias MJ, Cobo J, Tato M, De la Pedrosa EG, Gomez-Mampaso E, Moreno S. 2005. Linezolid for the treatment of multidrug-resistant tuberculosis. J. Antimicrob. Chemother. 56:180-185. http://dx.doi.org/10.1093/jac/dki148.
10. Park IN, Hong SB, Oh YM, Kim MN, Lim CM, Lee SD, Koh Y, Kim WS, Kim DS, Kim WD, Shim TS. 2006. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J. Antimicrob. Chemother. 58:701-704. http://dx.doi.org/10.1093/jac/dk1298.
11. Schecter GF, Scott C, True L, Raftery A, Flood J, Mase S. 2010. Linezolid in the treatment of multidrug-resistant tuberculosis. Clin. Infect. Dis. 50: 49-55. http://dx.doi.org/10.1086/648675.
12. Singla R, Caminero JA, Jaiswal A, Singla N, Gupta S, Bali RK, Behera D. 2012. Linezolid: an effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India. Eur. Respir. J. 39: 956-962. http://dx.doi.org/10.1183/09031936.00076811.
13. Migliori GB, Eker B, Richardson MD, Sotgiu G, Zellweger JP, Skrahina A, Ortmann J, Girardi E, Hoffmann H, Besozzi G, Bevilacqua N, Kirsten D, Centis R, Lange C. 2009. A retrospective TENET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur. Respir. J. 34:387-393. http://dx.doi.org/10.1183/09031936.00009509.
14. Cobelens FG, Heldal E, Kimerling ME, Mitnick CD, Podewils LJ, Ramachandran R, Rieder HL, Weyer K, Zignol M. 2008. Scaling up programmatic management of drug-resistant tuberculosis: A prioritized research agenda. PLoS Med. 5:el50. http://dx.doi.org/10.1371/journal.pmed.0050150.
15. Sotgiu G, Centis R, DAmbrosio L, Alffenaar JW, Anger HA, Caminero JA, Castiglia P, De Lorenzo S, Ferrara G, Koh WJ, Schecter GF, Shim TS, Singla R, Skrahina A, Spanevello A, Udwadia ZF, Villar M, Zampogna E, Zellweger JP, Zumla A, Migliori GB. 2012. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur. Respir. J. 40:1430-1442. http://dx.doi.org/10.1183/09031936.00022912.
16. Lee M, Lee J, Carroll MW, Choi H, Min S, Song T, Via LE, Goldfeder LC, Kang E, Jin B, Park H, Kwak H, Kim H, Jeon HS, Jeong I, Joh JS, Chen RY, Olivier KN, Shaw PA, Follmann D, Song SD, Lee JK, Lee D, Kim CT, Dartois V, Park SK, Cho SN, Barry CE, III 2012. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N. Engl. J. Med. 367:1508-1518. http://dx.doi.org/10.1056/NEJMoa1201964.
17. Brancusi F, Farrar J, Heemskerk D. 2012. Tuberculous meningitis in adults: A review of a decade of developments focusing on prognostic factors for outcome. Future Microbiol. 7:1101-1116. http://dx.doi.org/10.2217/fmb.12.86.
18. Garg RK. 1999. Tuberculosis of the central nervous system. Postgrad. Med. J. 75:133-140.
19. Lachnik J, Ackermann B, Bohrssen A, Maass S, Diephaus C, Puncken A, Stermann M, Bange FC. 2002. Rapid-cycle PCR and fluorimetry for detection of mycobacteria. J. Clin. Microbiol. 40:3364-3373. http://dx.doi.org/10.1128/JCM.40.9.3364-3373.2002.
20. Rupprecht TA, Pfister HW. 2005. Clinical experience with linezolid for the treatment of central nervous system infections. Eur. J. Neurol. 12:536-542. http://dx.doi.org/10.11111/1468-1331.2005.01001.X.
21. Thwaites GE, Nguyen DB, Nguyen HD, Hoang TQ, Do TT, Nguyen TC, Nguyen QH, Nguyen TT, Nguyen NH, Nguyen TN, Nguyen NL, Vu NT, Cao HH, Tran TH, Pham PM, Nguyen TD, Stepniewska K, White NJ, Farrar JJ. 2004. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N. Engl. J. Med. 351:1741-1751. http://dx.doi.org/10.1056/NEJMoa040573.
22. Dietze R, Hadad DJ, McGee B, Molino LP, Maciel EL, Peloquin CA, Johnson DF, Debanne SM, Eisenach K, Boom WH, Palaci M, Johnson JL. 2008. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 178:1180-1185. http://dx.doi.org/10.1164/rccm.200806-892OC.
23. Bressler AM, Zimmer SM, Gilmore JL, Somani J. 2004. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect. Dis. 4:528-531. http://dx.doi.org/10.1016/S14733099(04)01109-0.
24. Singh R, Manjunatha U, Boshoff HI, Ha YH, Niyomrattanakit P, Ledwidge R, Dowd CS, Lee IY, Kim P, Zhang L, Kang S, Keller TH, Jiricek J, Barry CE, III 2008. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 322:1392-1395. http://dx.doi.org/10.1126/science.1164571.
25. Marx GE, Chan ED. 2011. Tuberculous meningitis: Diagnosis and treatment overview. Tuberc. Res. Treat. 2011:798764. http://dx.doi.org/10.1155/2011/798764.
26. Nau R, Sorgel F, Eiffert H. 2010. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin. Microbiol. Rev. 23:858-883. http://dx.doi.org/10.112S/CMR.00007-10.
27. Yew WW, Chau CH, Wen KH. 2008. Linezolid in the treatment of difficult multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 12:345-346.
28. von der Lippe B, Sandven P, Brubakk O. 2006. Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB): A report of ten cases. J. Infect. 52:92-96. http://dx.doi.org/10T016/j.jinf.2005.04.007.
29. Di Paolo A, Malacarne P, Guidotti E, Danesi R, Del Tacca M. 2010. Pharmacological issues of linezolid: An updated critical review. Clin. Pharmacokinet. 49:439-447. http://dx.doi.org/10.2165/11319960-000000000-00000.
30. Bishop E, Melvani S, Howden BP, Charles PG, Grayson ML. 2006. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: A proposed protocol for monitoring therapy in complex patients. Antimicrob. Agents Chemother. 50:1599-1602. http://dx.doi.org/10.1128/AAC.50.4.1599-1602.2006.